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Abstract
Galectin-3 has been increasingly recognized as an important modulator of several biological func-
tions, by interacting with several molecules inside and outside the cell, and an emerging player in
numerous disease conditions. Galectin-3 exerts various and sometimes contrasting effects accord-
ing to its location, type of injury or site of damage. Strong evidence indicates that galectin-3 partici-
pates in the pathogenesis of diabetic complications via its receptor function for advanced glycation
end-products (AGEs) and advanced lipoxidation end-products (ALEs). AGEs/ALEs are produced to an
increased extent in target organs of complications, such as kidney and vessels; here, lack of galectin-
3 impairs their removal, leading to accelerated damage. In contrast, in the liver, AGE/ALE tissue
content and injury are decreased, because lack of galectin-3 results in reduced uptake and tissue
accumulation of these by-products. Some of these effects can be explained by changes in the expres-
sion of receptor for AGEs (RAGE), associated with galectin-3 deletion and consequent changes in
AGE/ALE tissue levels. Furthermore, galectin-3 might exert AGE/ALE- and RAGE-independent
effects, favoring resolution of inflammation and modulating fibrogenesis and ectopic osteogenesis.
These effects are mediated by intracellular and extracellular galectin-3, the latter via interaction with
N-glycans at the cell surface to form lattice structures. Recently, galectin-3 has been implicated in the
development of metabolic disorders because it favors glucose homeostasis and prevents the dele-
terious activation of adaptive and innate immune response to obesogenic/diabetogenic stimuli. In
conclusion, galectin-3 is an emerging all-out player in metabolic disorders and their complications
that deserves further investigation as the potential target of therapeutic intervention.
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Introduction
Galectins are an ancient lectin family defined by evolutionary con-
served amino acid sequences and by recognition of β-galactoside struc-
tures (Barondes et al. 1994). So far, 14mammalian galectins have been
identified, all of which contain a carbohydrate-recognition-binding
domain (CRD) of ∼130 amino acids. According to the number and
the organization of CRDs, members of galectin family have been clas-
sified into three subtypes: The prototype group, the chimera group and
the tandem repeat group (Hirabayashi and Kasai 1993).
Galectin-3 is the only vertebrate chimera-type galectin, that is,
having both a lectin domain and a non-lectin domain (Hirabayashi
and Kasai 1993). It has been increasingly recognized as an important
modulator of several biological functions and as an emerging player
in the pathogenesis of numerous disease conditions, including cancer,
immune/inflammatory and metabolic disorders. This review sum-
marizes the evidence supporting a major role of this lectin in the de-
velopment and progression of metabolic disorders and their
complications.
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Structure-function relationships of galectin-3
Galectin-3 is a 29- to 35-kDa protein, originally identified as Mac-2, a
32-kDa cell surface antigen expressed on murine thioglycollate-elicited
peritoneal macrophages (Ho and Springer 1982). Its structure consists
of two domains, the C-terminal CRD, with highly conserved residues
between members of the family, and the N-terminal domain, with a un-
ique short end continuing into an intervening proline-glycine-alanine-
tyrosine-rich repeat motif (Liu 1993; Barondes et al. 1994) (Figure 1).
Galectin-3 expression in tissues appears to be developmentally regu-
lated, being more abundant during embryogenesis and development
than in the adult life, when it is detected in various epithelial cells, car-
tilage and bone as well as in inflammatory cells, either constitutively or
in an inducible fashion (Aubin et al. 1995; Liu et al. 2002).
Galectin-3 shows a ubiquitous localization within the cell. Al-
though lacking a signal sequence for transfer into the endoplasmic re-
ticulum and Golgi compartments and entry into classical secretory
pathways (Menon and Hughes 1999), galectin-3 is also secreted into
the extracellular space, where it is found both on the cell surface and in
the extracellular space (Dumic et al. 2006). Its intracellular distribu-
tion depends on the cell cycle, being mainly cytoplasmic in quiescent
cells, and nuclear in replicating cells (Liu et al. 2002). Phosphorylation
at N-terminal serine 6 is a key event for galectin-3 shuttling from the
nucleus to the cytoplasm, where only the phosphorylated form can be
detected (Liu et al. 2002).
When bound to glycoconjugates, galectin-3 is also capable
of peptide–peptide homodimeric association involving the N-terminal
domain (Hsu et al. 1992; Massa et al, 1993). N-terminus-dependent
cross-linking of galectin-3 was shown to be mediated by tissue-type
transglutaminase, with one lysine and two glutamine residues serving
as amine receptor and acceptor, respectively (Mehul et al. 1995).
However, when not bound to glycoconjugates, it self-associates in a
manner that is dependent on the C-terminal domain and is inhibitable
by the lectin’s carbohydrate ligands (Kuklinski and Probstmeier 1998;
Yang et al, 1998).
Extracellular galectin-3 interacts with the β-galactoside residues of
several extracellular matrix (ECM) and cell surface glycoproteins via
the CRD; this is the classical lectin–glycoconjugate interaction. At the
cell surface, galectin-3 forms multimeric structures up to pentamers
driven by increasing concentrations of multivalent glycoprotein li-
gands, resulting in higher order lattices or microdomains with
irregular geometry (Demetriou et al. 2001; Ahmad et al., 2004). Affin-
ity for glycoproteins is dependent on metabolite availability to the hex-
osamine and Golgi N-glycosylation pathways, which determine the
number and structure of N-acetyllactosamine (Galβ1,4GlcNAc)-con-
taining Asn (N)-linked oligosaccharides (N-glycans) (Dennis, Nabi,
et al. 2009). The galectin-glycoprotein lattice is involved in the regulation
of receptor clustering, endocytosis and signaling (Dennis, Lau, et al.
2009). Recently, a novel function of galectin-3 has been demonstrated,
which is related to its ability to crosslink in heterogeneous lattices on the
cell surface. In fact, galectin-3 has been shown to regulate the biogenesis
of a subpopulation of clathrin-independent carriers (CLICs) involved in
the endocytosis of selected cargo proteins (Lakshminarayan et al. 2014).
In the model proposed for galectin-3-driven CLIC biogenesis, galectin-3
serves as an endocytic adaptor that co-clusters glycosylated cargos and
glycosphingolipids at the plasma membrane, which leads to both mem-
brane bending and clathrin-independent formation of the endocytic pit
(Du Toit 2014). Interactions of intracellular galectin-3 occur via pep-
tide–peptide, not lectin–glycoconjugate associations (Liu et al. 2002), ex-
cept for binding to cytokeratins (Goletz et al. 1997). These structural
properties enable galectin-3 to bind several proteins, thus exerting mul-
tiple functions that make it a broad-spectrum biological response modi-
fier involved in several disease conditions (Iacobini et al. 2003).
Intracellular galectin-3 acts as a pre-mRNA splicing factor (Dagher
et al. 1995). Both galectin-1 and galectin-3 have been found to asso-
ciate with nuclear ribonucleoprotein complexes including the spliceo-
some and, by means of cell-free assay, have been shown to be required
splicing factors (Haudek et al. 2010). However, in vivo involvement of
these galectins in spliceosome function is not yet understood.
Intracellular galectin-3 also regulates the cell cycle, through a G1
or G2/M arrest, via downregulation of cyclin A and E, upregulation of
p21 and p27 cyclin inhibitors and hypophosphorylation of Rb protein
(Kim et al. 1999). Moreover, galectin-3 has been shown to be a key
regulator of the Wnt/β-catenin signaling pathway because of its ability
to interact with β-catenin and translocate it into the nucleus, with con-
sequent stimulation of cyclin D1 and c-myc expression (Shimura et al.
2004). In addition, galectin-3 has structural similarities with
β-catenin; like this, it is phosphorylated by casein kinase 1 and glyco-
gen synthase kinase-3β, a critical event for cytoplasmic shuttling of
both proteins, and binds axin at the same sequence motif as β-catenin
(Shimura et al. 2005). Another mechanism for the regulation of cell
growth and differentiation is the immobilization into the galectin-3
lattice of glycoprotein receptors of several growth factors, including
epidermal growth factor, insulin-like growth factor, fibroblast growth
factor and platelet-derived growth factor (Lau et al. 2007). The
cell-cycle regulating properties of galectin-3 include the control of
cell proliferation, death and differentiation. Galectin-3 promotes cell
proliferation (Yang et al. 1996; Inohara et al. 1998) and favors cell
survival by protecting from apoptosis induced by a variety of death
signals (Yang et al. 1996; Akahani et al. 1997). In particular, the anti-
apoptotic activity of galectin-3 seems to be related to its sequence
homology and association with bcl-2 (Yang et al. 1996; Akahani
et al. 1997). By virtue of its pro-proliferative and antiapoptotic action,
galectin-3 is considered as an immediate early gene possibly implicated
in tumor growth, as shown by the abnormal expression of galectin-3
reported in several neoplasms (Liu and Rabinovich 2005). However,
galectin-3 can also be pro-apoptotic and mediate T cell and neutrophil
death (Yang et al. 2008).
Extracellular galectin-3 regulates cell adhesion in a dual manner.
Cell surface galectin-3 promotes homo- and heterotypic cell-to-cell in-
teractions by serving as a cross-linking bridge between adjacent cells
through attachment to a complementary serum glycoprotein(s)Fig. 1. Galectin-3 structure. Aa, aminoacids.
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(Inohara and Raz 1995; Friedrichs et al. 2007). On the contrary,
galectin-3 downregulates cell adhesion to the ECM component lam-
inin via an association with the α1β1-integrin receptor in a
lactose-inhibitable manner, thus producing an antiadhesive effect
(Ochieng et al. 1998; Friedrichs et al. 2008). Moreover, galectin-3
was found to interact with branched N-glycans on integrin α5β1,
thus promoting turnover of focal adhesions and cell spreading and
motility (Lagana et al. 2006). This dual function of galectin-3 on
cell adhesion has made this lectin an interesting target for the study
of tumor progression and invasiveness (Hughes 2001).
Another important function of galectin-3 is the modulation of im-
mune/inflammatory function, with both pro- and antiinflammatory
actions, depending on multiple factors, such as type of inflammatory
setting and target cell/tissue (Figure 2) (Dumic et al. 2006). In acute
settings, galectin-3 is a key component of the host defense mechanism
against microbial infections. When secreted or externalized, galectin-3
may affect immune/inflammatory cells by an autocrine/paracrine
mechanism. It favors the acute phase of inflammation because of its
involvement in the (i) initiation phase, including chemoattraction of
monocytes and macrophages, adhesion of neutrophils to laminin
and endothelial cells and recognition of microbes (Mey et al. 1996;
Sano et al. 2000; John et al. 2002); (ii) induction of cellular effector
functions, such as respiratory burst in neutrophils and monocytes,
and phagocytosis (Yamaoka et al. 1995; Karlsson et al. 1998; Sano
et al. 2003; Farnworth et al. 2008) and (iii) modulation of apoptotic
cell death (Hsu and Liu 2004; Farnworth et al. 2008). While the ini-
tiation phase is mediated by extracellular galectin-3, the subsequent
events are known to be modulated by intracellular galectin-3. It also
participates in allergic reactions by inducing mediator release by mast
cells (Frigeri et al. 1993). Studies in galectin-3 knockout mice with ex-
perimentally induced peritonitis have provided strong evidence of its
pro-inflammatory effects (Hsu et al. 2000). Nonetheless, in chronic in-
flammation, galectin-3 appears to favor resolution of the process by
limiting tissue injury or promoting repair. In fact, it inhibits
lipopolysaccharide-mediated inflammation (Li et al. 2008), promotes
T-cell apoptosis (Fukumori et al. 2003) and negatively regulates T-cell
receptor (TCR)-mediated T-cell activation. In particular, Chen et al.
(2009) attributed this effect to TCR downregulation promoted by intra-
cellular galectin-3, whereas Demetriou et al. (2001) showed that the
galectin-glycoprotein lattice on the cell surface restricts TCR recruitment
and clustering, which are required for T-cell activation (Grigorian et al.
2009). This latter mechanism was also found to inhibit T-cell growth
and T helper (Th) 1 differentiation (Morgan et al. 2004). Moreover,
MacKinnon et al. (2008) have shown that upregulation of galectin-3 ex-
pression is a feature of the alternative macrophage (M2) phenotype and
that release of galectin-3 by alternatively activatedmacrophages sustains
the M2 phenotype contributing to some of its functions in vivo. Like-
wise, Karlsson et al. (2009) have supported the view that galectin-3,
by functioning as an opsonin, favors the phagocytic clearance of apop-
totic neutrophils by macrophages, a process of crucial importance for
termination of acute inflammation. Along the same lines, Caberoy
et al. (2012) have recently shown that galectin-3 is a legitimate Mer re-
ceptor tyrosine kinase-specific “eat-me” signal that stimulates phagocyt-
osis of apoptotic cells and cellular debris. Finally, galectin-3 facilitates
repair of tissue injury by promoting epithelial-mesenchimal transition
(EMT) (MacKinnon et al. 2012) and fibrogenesis (Henderson and
Sethi 2009). Also this effect has been related to the ability of galectin-3
to bindN-glycans on transforming growth factor-β (TGF-β) receptors at
the cell surface, thus delaying their removal (Partridge et al. 2004), but
also to the induction of the M2 phenotype (MacKinnon et al. 2008).
Finally, cell surface (and circulating) galectin-3 serves as a receptor
for the advanced glycation end-products (AGEs) and advanced lipox-
idation end-products (ALEs), which are known to play a major role in
the pathogenesis of long-term diabetic complications (Pugliese 2008).
Galectin-3 as an AGE/ALE-receptor
AGEs/ALEs accumulate in metabolic disorders via several mechan-
isms (Baynes and Thorpe 1999; Negre-Salvayre et al. 2008), including
(i) enhanced carbohydrate and/or lipid substrate availability, because
of hyperglycemia and/or hyperlipidemia; (ii) increased oxidative me-
tabolism, which causes oxidation of glucose and Amadori products
(glycoxidation) or lipids (lipoxidation); (iii) increased nonoxidative
metabolism with accumulation of reducing sugars other than glucose,
Fig. 2. Immunomodulatory actions of galectin-3: Proinflammatory and antiinflammatory (in italics) effects. *Phagocytosis of apoptotic bodies and cellular debris
might be antiinflammatory by avoiding “secondary necrosis”. E, endogenous galectin-3; R, recombinant galectin-3; LPS, lipopolysaccharide; IL, interleukin.
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due to increased glucose flux through glycolysis and polyol pathway
(intracellular glycation), which results in the generation of the AGE-
precursor methylglyoxal and (iv) impaired detoxification caused by
consumption of cofactors of detoxifying enzymes and possibly re-
duced liver/kidney clearance, due to the presence of complications
such as liver disease and renal failure.
AGEs and ALEs induce tissue injury by exerting direct, physico-
chemical effects, which lead to changes in enzymatic activity, ligand
binding, half-life and immunogenicity (Brownlee 1995), but also in-
direct, receptor-mediated effects. In fact, epitopes contained in AGEs
or ALEs constitute a prominent set of damage-associated molecular
patterns, which are recognized by pattern recognition receptors of in-
nate immunity (Chou et al. 2008).
In 1995, Vlassara et al. (1995) found that galectin-3 exhibits
high-affinity binding for 125I-AGE-bovine serum albumin (BSA) with
saturable kinetics. Binding, whichwas fully blocked by excess unlabeled
naturally formed or, under certain circumstances, synthetic AGEs, was
not inhibited or onlyweakly inhibited by either early glycation products
or lectin-binding carbohydrates, such as lactose. Scatchard plot analysis
was consistent with a single class of binding sites and a degree of affinity
similar to that of the AGE-receptor on macrophages and higher than
that for carbohydrates. Binding activity was retained by the C-terminal
domain and even enhanced by removal of the N-terminal domain, and
was located to a site distinct from the CRD, as it was not inhibited
by lectin-binding carbohydrates. Interestingly, oligomerization of
galectin-3 onto the cell surface appeared to be significant for displaying
the AGE-receptor function, as indicated by the distinct patchy distribu-
tion shown by galectin-3 when interacting with AGEs. In addition to
binding AGEs, galectin-3 plays a role in endocytosis of modified low
density lipoproteins (LDLs), which carry both ALE and AGE structures
(Virella et al. 2004). In Chinese hamster ovary cells overexpressing
human galectin-3, degradation of labeled AGE-BSA, acetylated LDL
and oxidized LDL were specifically inhibited by any of these unlabeled
ligands, but not, for instance, by unmodified LDL or high density lipo-
protein (Zhu et al. 2001). However, to date there is no clear evidence
that galectin-3 acts as a typical surface receptor, since there is no con-
sensus transmembrane spanning domain in its sequence (Barondes et al.
1994). Moreover, the molecular events underlying galectin-3-
dependent AGE/ALE binding, internalization and degradation are still
undefined. It is tempting to speculate that the galectin-3 lattice on the
cell surface and its role in CLIC biogenesis may be involved in this func-
tion (Figure 3). This hypothesis is supported by the finding that either
membrane-derived or recombinant galectin-3 mobilizes and forms
high-molecular-weight aggregates on the cell surface in a time-
dependent manner after exposure to AGEs (Vlassara et al. 1995). In
addition, immunoprecipitation, affinity studies and ligand blot analysis
showed that, in these aggregates, galectin-3 is associated with the
90-kDaAGE-binding polypeptide (AGE-receptor 2) and other twomo-
lecules with AGE-binding activity (Vlassara et al. 1995). Therefore,
these studies suggest a physical and possibly functional association of
galectin-3 with other AGE-receptors, which might also occur through
the galectin-glycoprotein lattice. However, also intracellular galectin-3
might be involved in AGE/ALE receptor function by binding the by-
products forming inside the cell. Altogether, these data indicate ligand
specificity and support the concept that galectin-3 is involved in the up-
take and removal of AGEs/ALEs, as opposed to receptor for AGEs
(RAGE), the first-identified AGE-receptor. This 35-kDa member of
the immunoglobulin superfamily of receptors has three domains: A
cytoplasmic, a transmembrane spanning and an extracellular domain,
which is secreted as soluble RAGE. In addition to AGEs, RAGE
binds β-sheet fibrils, calgranulins and amphoterin, thus participating
also in amyloidoses, immune/inflammatory disorders and tumor
growth (Schmidt et al. 2001). AGE/ALE binding to RAGE is associated
with cell activation (Thornalley 1998), via receptor-mediated gener-
ation of reactive oxygen species (ROS) (Basta et al. 2005). ROS trigger
proinflammatory signaling pathways causing mitogen-activated protein
kinase (MAPK)-dependent activation of transcription factors such as
nuclear factor κB (NFκB) (Bierhaus et al. 1997; Lander et al. 1997),
which in turn modulate the gene expression of several cytokines (Bier-
haus et al. 2005; Ramasamy et al. 2005), with consequent induction of
apoptosis, inflammation and fibrosis leading to tissue injury.
Thus, galectin-3 and RAGE appear to exert opposite actions as
AGE/ALE-receptors and, hence, to participate in the pathogenesis of
metabolic disorders and their complications in oppositeways. Galectin-3
Fig. 3. Hypothetical mechanism of galectin-3 AGE/ALE-receptor function involving formation galectin-glycoprotein lattice on the cell surface and CLIC biogenesis.
CLIC, clathrin-independent carrier; AGE, advanced glycation end-product; ALE, advanced lipoxidation end-product.
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plays a protective, antiinflammatory role by favoring removal of AGEs/
ALEs, whereas RAGEmediates the proinflammatory effects of these by-
products (Pricci et al. 2000; Iacobini et al. 2003). In addition, both recep-
tors have AGE/ALE-independent effects that may be important in the
development and progression of these disease conditions.
In the following sections, wewill (i) discuss the existing data on the
well-recognized role of galectin-3 in vascular and metabolic complica-
tions of diabetes and the metabolic syndrome; and (ii) critically review
the more recent evidence on the involvement of this lectin in the patho-
genesis of metabolic disorders.
Galectin-3 in target tissue damage associated
with diabetes and related metabolic disorders
Several studies have focused on the role of galectin-3 in models of
metabolic disorders, such as experimentally induced diabetes, AGE in-
jection, the normal aging process and feeding a high fat diet (HFD).
These studies have shown that galectin-3 plays an important role in
the regulation of the molecular processes underlying injury in all or-
gans and tissues that are affected by complications of these disorders.
Nephropathy
The kidney is a main target organ of microvascular complications of
diabetes (Reutens 2013). During development, galectin-3 is expressed
widely in epithelial cells, in the apical domains of ureteric bud
branches of the metanephros. In the mature kidney, it is only expressed
sparsely in the distal tubules and by a subset of cells of the collecting
ducts, the α-intercalated cells (Winyard et al. 1997). We have reported
that expression of galectin-3, which is absent or weak at the glomeru-
lar/mesangial level in normal adult rats, grows with increasing age; ex-
pression was further enhanced in diabetic rats, where it was detected
earlier and to a greater extent. Likewise, galectin-3 expression was in-
duced or upregulated in cultured mesangial cells by incubation under
high glucose conditions or upon exposure to AGEs (Pugliese et al.
2000). Similar findings were reported in cultured endothelial cells in
response to AGEs (Stitt et al. 1999).
We have reported that galectin-3 knockout mice develop acceler-
ated diabetic glomerulopathy, when compared with the wild-type an-
imals (Table I) (Pugliese et al. 2001). We obtained similar findings in
aging mice (Iacobini et al. 2005), in mice injected with the ALE/AGE
Nε-carboxymethyllysine (CML)-modified mouse serum albumin
Table I. Effects of galectin-3 ablation, overexpression, or inhibition on micro- and macrovascular complications of diabetes and related
metabolic disorders
Authors, year Experimental model Disease outcome Major findings Mechanisms
Nephropathy
Pugliese et al. 2001 Diabetes: STZ induction
(Gal-3 ablation)
Accelerated
glomerulopathy
Increased proteinuria,
albuminuria, mesangial
expansion, glomerulosclerosis,
glomerular cell apoptosis and
ECM protein expression
Increased circulating and renal
tissue AGE/ALE levels Increased
renal cortex RAGE expression
Increased AGE/ALE-induced
tissue inflammation and
injuryIacobini et al. 2005 Aging (Gal-3 ablation)
Iacobini et al. 2004 AGEs: CML
administration (Gal-3
ablation)
Iacobini et al. 2009b Dyslipidemia: HFD
(Paigen) (Gal-3 ablation)
Retinopathy
Canning et al. 2007 Diabetes: STZ induction
(Gal-3 ablation)
Attenuated early
retinal changes
Reduced inner blood-retinal
barrier dysfunction and
junctional disruption
Reduced (AGE-induced)
upregulation of vascular
endothelial growth factor
Stitt et al. 2005 Oxygen-induced
proliferative retinopathy
plus perfusion of
preformed AGEs (Gal-3
ablation)
Attenuated advanced
retinal lesions
Reduced AGE-mediated increase
in retinal ischemia and
restoration of the neovascular
response
Prevention of AGE-mediated
suppression of angiogenesis
McFarlane et al. 2005 Human retinal pigment
epithelium exposed to
AGEs (Gal-3
overexpression)
Attenuated response to AGE
exposure
Reduced AGE-induced
upregulation of vascular
endothelial growth factor
Atherosclerosis
Iacobini et al. 2009a Atherogenic HFD (Paigen)
(Gal-3 ablation)
Accelerated
atherosclerosis
Greater lesion area, length and
complexity (necrotic core,
fibrous cap, cholesterol clefts)
Increased circulating and plaque
AGE/ALE levels
Increased plaque RAGE
expression
Increased AGE/ALE-induced
tissue inflammation and
injury
Increased recruitment of
monocytes/ macrophages
and, particularly,Th1
lymphocytes
Nachtigal et al. 2008 ApoE null mice, chow diet
(Gal-3 ablation)
Attenuated
atherosclerosis
Reduced lesion number, but not
size, in aged mice (9 to 11
months)
Lower number of perivascular
inflammatory infiltrates and
mast cells
MacKinnon et al. 2012 ApoE null mice,
atherogenic diet (Gal-3
ablation/inhibition)
Attenuated
atherosclerosis
Reduced lesion area, collagen
content and M2 polarization
Inducible nitric oxide synthase
to arginase switch reversal
STZ, streptozotocin; Gal-3, galectin-3; AGEs, advanced glycation end-products; CML, Nε-carboxymethyllysine; HFD, high fat diet; ALEs, advanced lipoxidation
end-products; RAGE, receptor for AGEs; M2, alternative macrophage; Th, T helper.
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(Iacobini et al. 2004), and in mice fed a proatherogenic HFD, an ex-
perimental animal model of dyslipidemia (Iacobini et al. 2009b)
(Table I). In all these experimental conditions, galectin-3 gene deletion
was associated with more severe changes in renal function and struc-
ture than in coeval wild-type mice, as shown by the higher increases in
proteinuria, albuminuria, glomerular sclerosis, glomerular and me-
sangial areas and glomerular cell apoptosis and ECM protein expres-
sion. Another observation was that both circulating and renal tissue
levels of AGEs increased more markedly in response to diabetes,
aging, AGE-injection and HFD, as did renal cortex RAGE expression,
which was upregulated even in control animals (Pugliese et al. 2001;
Iacobini et al. 2004, 2005; Iacobini et al. 2009b). These data are in
contrast with those obtained by other investigators in different models
characterized by acute inflammation and fibrosis, also associated with
increased galectin-3 expression. In fact, tubular atrophy and intersti-
tial fibrosis after renal transplantation (Dang et al. 2012), renal tissue
damage triggered by ischemia and reperfusion injury (Fernandes Ber-
tocchi et al. 2008) and renal fibrosis induced by unilateral ureteric ob-
struction (Henderson et al. 2008; Okamura et al. 2011) were
attenuated by deletion of galectin-3 gene. However, a protective effect
of various galectins, including galectin-3, was observed in the experi-
mental rat model of nephrotoxic serum nephritis, via reduction of
macrophage influx into the kidney (Tsuchiyama et al. 2000).
Retinopathy
Retinopathy is another major microvascular complication of diabetes
(Yau et al. 2010). Galectin-3 expression was observed in retinal pig-
ment epithelium (RPE) (McFarlane et al. 2005) and Muller cells (Ue-
hara et al. 2001), and was shown to increase in RPE upon exposure to
AGEs (McFarlane et al. 2005).
Canning et al. (2007) found that galectin-3 gene deletion effective-
ly prevents early retinal changes associated with streptozotocin-
induced diabetes, such as inner blood-retinal barrier dysfunction,
junctional disruption and vascular endothelial growth factor expres-
sion, thus suggesting that this lectin favors initial retinal lesions. How-
ever, in a previous report, the same group had evaluated the more
advanced retinal lesions by the use of a mouse model of oxygen-
induced proliferative retinopathy. In wild-type mice, treatment with
AGE-modified BSA resulted in a significant increase in inner retinal
ischemia and a reduction in neovascularization as compared with non-
AGE controls, whereas deletion of galectin-3 gene abolished the AGE-
mediated increase in retinal ischemia and restored the neovascular
response to that seen in controls (Stitt et al. 2005). Moreover, a
human cell line of retinal pigment epithelium showed weaker induc-
tion of vascular endothelial growth factor in response to AGEs,
when transfected to overexpress galectin-3 (McFarlane et al. 2005).
The results of these studies are summarized in Table I. Unfortunately,
no further study has been conducted to clarify the role of galectin-3 in
the progression of this invalidating complication of diabetes.
Atherosclerosis
Cardiovascular disease is the main cause of morbidity andmortality in
diabetic patients and diabetes is a potent accelerator of atherosclerosis
(Stamler et al. 1993). In vascular smooth muscle cells (VSMCs),
galectin-3 is not expressed in the quiescent state, but is induced in pro-
liferating cells (Arar et al. 1998). Moreover, it is expressed in foam
cells from arteries of experimental animal models of atherogenesis
(Arar et al. 1998) as well as of human patients with advanced athero-
sclerotic lesions, in whom galectin-3 expression was also found in
VSMCs, though to a lesser extent than in foam cells (Nachtigal
et al. 1998). More recently, Papaspyridonos et al. (2008). found
that galectin-3 is upregulated in unstable versus stable regions, as clas-
sified on the basis of macroscopic morphologic features, from plaque
specimens of carotid endarterectomies (CEAs) and that it is expressed
by macrophages in the aortas of ApoE null mice on an HFD, thus sug-
gesting a role for galectin-3 as a marker of atherosclerotic plaque pro-
gression . We confirmed that, in unstable, inflamed plaque regions
fromCEA specimens, galectin-3 is expressedmainly, if not exclusively,
by lipid-laden and infiltrating inflammatory cells, but we also found
that, in fibrocalcific, noninflamed plaque areas where macrophages
are rare and VSMCs predominate, most VSMCs express galectin-3
(Menini et al. 2013). Also endothelial galectin-3 might play a role in
atherosclerosis, as suggested by the observations that upregulation of
galectin-3 is part of the vascular response to diabetes (Darrow et al.
2011) and that, together with galectin-1, galectin-3 is a partner for
von Willebrand factor (VWF), playing a role in the modulation of
VWF-mediated thrombus formation (Saint-Lu et al. 2012). Further-
more, the absence of galectin-1 and galectin-3 was found to be asso-
ciated with more efficient formation of platelet-decorated VWF strings
along the endothelial surface and with enhanced formation of arterial
thrombi (Saint-Lu et al. 2012).
Several studies have been conducted to investigate the role of
galectin-3 in atherogenesis (Table I). We have reported that galectin-3
knockout animals on a proatherogenic HFD show accelerated athero-
sclerosis, with greater lesion area and length (Iacobini et al. 2009a).
Furthermore, mice lacking galectin-3 developed complex lesions,
that is, a core of lipids and cell debris surrounded by a fibrous cap, as-
sociated with extensive recruitment, adhesion and infiltration of
mononuclear cells, formation of foam cells within the intima and in-
vasion of the media, apoptosis of VSMCs and macrophages and pres-
ence of cholesterol clefts. In contrast, in wild-type mice, only fatty
streaks were seen. As in the kidney, acceleration of lesions was asso-
ciated with increased aortic content of CML and 4-hydroxy-2-
nonenal, two major AGEs/ALEs and with enhanced expression of
RAGE. Moreover, galectin-3 knockout mice on HFD showed striking
inflammatory features, with more abundant recruitment of mono-
cytes/macrophages and presence of an extensive infiltrate of T lympho-
cytes with predominant Th1 phenotype. In contrast to these findings
from our group, two independent studies conducted in ApoE-null
mice, a mouse model of atherosclerosis, have suggested a pathogenic
role of galectin-3 in atherogenesis. In the first study, Nachtigal et al.
(2008) showed that ApoE null mice on a standard chow develop atte-
nuated atherosclerosis when crossbred with galectin-3 knockout mice.
A possible explanation for this discrepancy is that, in this report, wild-
type micewere on a C57BL/6J background, whereas galectin-3 knock-
out mice were on a 129 background, a strain which has long been
recognized to be less prone to develop atherosclerotic lesions than
the C57BL/6J (Paigen et al. 1985; Maeda et al. 2007). Moreover, dif-
ferences in lesion number, but not size, were detected only at the oldest
age examined, when the number of animals was small. More recently,
MacKinnon et al. (2013) have also reported that galectin-3 ablation or
administration of citrus pectin, a nonspecific inhibitor of galectin-3
(Kumar and Deutscher 2008), decreases atherosclerosis in ApoE-null
mice fed a high-cholesterol western diet. In addition to reporting a re-
duction of lesion area at the level of the thoracic aorta, the aortic arch
and the brachiocephalic artery, these authors also found that
galectin-3 ablation induced a unique plaque phenotype, characterized
by reduced M2 macrophage polarization, due to reversal of the indu-
cible nitric oxide synthase to arginase switch, and decreased collagen
content (MacKinnon et al. 2013). However, these are two features of
increased plaque vulnerability (MacKinnon et al. 2008) and, hence,
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their occurrence is in contrast with a reduced atherosclerotic burden. A
final consideration about these controversial findings is that results in
double knockout mice could be related to unknown specific interac-
tions between the two genotypes.
More recently, we have focused our attention onto another funda-
mental process in vascular disease, that is, calcification. Though ath-
erosclerotic calcification is triggered by inflammation, it correlates in
a dual manner with inflammation and plaque instability, depending
on the pattern of calcium deposition. In fact, previous studies have
reported an association of spotty or granular calcification (microcal-
cification), and an inverse relation of diffuse, homogeneous calcifica-
tion (macrocalcification), with morphological (Virmani et al. 2003)
and clinical (Ehara et al. 2004; Shaalan et al. 2004; Nandalur et al.
2007; Kataoka et al. 2012) features of plaque instability. As men-
tioned above in this section, we found that galectin-3 is expressed
in macrophages and infiltrating inflammatory cells from unstable pla-
que regions with microcalcification, predominantly in the cytoplasm,
but also in VSMCs from fibrous areas and especially from regions ad-
jacent to macrocalcifications, mainly in the nucleus. Moreover, in
macrocalcified plaques, galectin-3 showed a pattern of positivity simi-
lar to that of the VSMCmarker α-smooth muscle actin and the mark-
er of osteogenic differentiation alkaline phosphatase. In contrast,
RAGE positivity was almost confined to microcalcified, unstable pla-
ques, and was typically observed in regions rich in foam cells and/or
inflammatory infiltrate (Menini et al. 2013). These differences in lo-
calization prompted the hypothesis that these two receptors have di-
verging effects also on the pattern of vascular calcification, with
galectin-3 favoring macrocalcification and RAGE favoring microcal-
cification. This hypothesis was confirmed by the finding that VSMC
osteogenic differentiation induced by calcification medium is im-
paired at both the morphological and molecular level in cells lacking
galectin-3 (Menini et al. 2013). These data are consistent with the
findings that, in the skeletal tissue, galectin-3 is a downstream target
of Runt-related transcription factor 2, the key regulator of osteogenic
differentiation (Stock et al. 2003), participates in the process of endo-
chondral bone formation (Colnot et al. 1999), and suppresses upre-
gulated osteoclastogenesis (Li et al. 2009). Moreover, cells lacking
galectin-3 showed blunted activation of Wnt/β-catenin signaling, a
key event in osteoblastogenesis (Glass and Karsenty 2007), and upre-
gulation of RAGE. However, silencing of this receptor restored only
partly the abnormal differentiation process in VSMCs lacking
galectin-3, whereas addition of the RAGE ligand CML mimicked in
the wild-type cells, or exacerbated in the VSMCs from knockout ani-
mals, the abnormal osteogenic response to calcification medium (Me-
nini et al. 2013).
Finally, several rodent models of pressure overload (Sharma et al.
2004; Calvier et al. 2013; Yu et al. 2013) and aortic constriction (Yu
et al. 2013) also exhibited increased myocardial and vascular expres-
sion of galectin-3. However, infusion of this lectin in pericardial sac of
normal rats induced myocardial fibrosis and left ventricular dysfunc-
tion (Sharma et al. 2004; Liu et al. 2009), which were prevented by
N-acetyl-seryl-aspartyl-lysyl-proline, a galectin-3 blocker (Liu et al.
2009). Other inhibitors of galectin-3, modified citrus pectin and
N-Lac, respectively, prevented vascular fibrosis induced by aldoster-
one (Calvier et al. 2013) and cardiac remodeling occurring in both
homozygous transgenic TGRmRen2-27 (Ren-2) rats and mice sub-
jected to transverse aortic constriction (Yu et al. 2013). Galectin-3
knockout mice were also protected from the profibrotic effects of al-
dosterone treatment (Calvier et al. 2013) and transverse aortic con-
striction (Yu et al. 2013).
Liver disease
Nonalcoholic fatty liver disease (NAFLD), the most prevalent chronic
liver disease worldwide (Clark 2006), is a common metabolic compli-
cation of obesity and type 2 diabetes (Angulo 2007; Targher et al.
2007). It encompasses various disease conditions, from simple stea-
tosis to nonalcoholic steatohepatitis (NASH), cirrhosis and possibly
hepatocellular carcinoma (Erickson 2009). The liver is the main cata-
bolic site for AGEs/ALEs, as indicated by the findings that plasma
ALE/AGE levels increase markedly in patients with liver cirrhosis, cor-
relate with the severity of the disease and inversely with residual liver
function, and decrease after liver transplantation (Se ̌beková et al.
2002). Tracer studies indicated that more than 90% of BSA-AGE in-
jected into rats is removed from circulation by sinusoidal liver cells,
endothelial cells more than Kupffer cells (Smedsrød et al. 1997).
Since AGE/ALE removal occurs via receptor-mediated endocytosis
(Smedsrød et al. 1997) and subsequent degradation by detoxifying en-
zymes (Negre-Salvayre et al. 2008), receptors for these by-products
play a fundamental role in this function. While RAGE is found pre-
dominantly in hepatocytes (Butscheid et al. 2007), galectin-3 (Butsc-
heid et al. 2007) and scavenger receptors (Suzuki et al, 1997) are
highly expressed in sinusoidal liver endothelial and Kupffer cells
and, hence, are the principal candidates for the AGE/ALE scavenging
function. Our studies in liver sinusoidal endothelial cells showed that
galection-3 has a major role in the uptake of these by-products (Iaco-
bini et al. 2011), at variance with scavenger receptor A and CD36
(Matsumoto et al. 2000; Nakajou et al. 2005). Finally, the levels of
galectin-3, as those of RAGE, were reported to increasewith the extent
of liver damage (Butscheid et al. 2007).
Contrasting data have been reported on the role of galectin-3 in the
development of NAFLD (Table II). In 2006, Nomoto et al. (2006) re-
ported that the absence of galectin-3 in male mice was associated with
clinical and pathological features similar to those of NAFLD. At
6 months, the livers of chow-fed galectin-3 knockout mice displayed
mild-to-severe fatty change at histological examination; the liver
weight per body weight ratio, serum alanine aminotransferase values
and liver triglyceride and lipid peroxide levels were significantly in-
creased as compared with wild-type mice. Moreover, 2 years later,
the same group published data demonstrating that, at the age of
15 months or later, galectin-3 knockout mice developed dysplastic
liver nodules and hepatocellular carcinoma; again, these pathological
conditions occurred spontaneously (Nakanishi et al. 2008). However,
these observations have not been replicated by other investigators, in-
cluding our group, thus remaining an isolated finding, possibly specific
of the CD1 background of the galectin-3 knockout mice used in these
studies. Instead, we demonstrated that the same galectin-3 knockout
mice that showed an acceleration of renal and aortic lesions when
fed a proatherogenic HFD were protected from diet-induced NASH,
with attenuation of inflammation, hepatocyte injury and fibrosis (Iaco-
bini et al. 2011). In fact, NASH was invariably detected in the wild-
type animals, with marked fibrosis even of the bridging type, portal
and lobular inflammation and signs of hepatocyte degeneration,
such as ballooning, Mallory’s and Councilman’s bodies and focal ne-
crosis. Conversely, in galectin-3 knockout mice, lesions of this kind
were observed to a much lower extent and only in a few animals.
These features were associated with reduced upregulation of hepatic
fatty acid synthesis and oxidation causing less fat deposition as well
as decreased oxidative stress, and possibly insulin resistance. What is
more, in contrast to what observed in the kidney and aorta, but con-
sistent with the attenuation of NASH, AGE/ALE levels (and RAGE ex-
pression) were decreased in the liver, in spite of increased circulating
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levels of these harmful by-products. Our data are consistent with the
observation that galectin-3 disruption attenuated ECM production
both in vitro, in hepatic stellate cell cultures, and in vivo, in the
model of CCL4-induced cirrhosis (Henderson et al. 2006). Also liver
fibrosis and cirrhosis induced by thioacetamide were reversed by
GR-MD-02 (galactoarabino-rhamnogalaturonan) and GM-CT-01
(galactomannan), two galectin-3 inhibitors (Traber et al. 2013).
Galectin-3: Only a “stooge” of RAGE? Does galectin-3
play only a supportive role through modulation of RAGE
expression?
Altogether, the existing data support the concept that galectin-3 is a
marker of tissue damage, which may be either attenuated or aggra-
vated by this lectin depending on the type of injurious stimulus and/
or the target organ. In the above mentioned models of renal, myocar-
dial and liver fibrosis (Sharma et al. 2004; Henderson et al. 2006,
2008; Fernandes Bertocchi et al. 2008; Liu et al. 2009; Okamura
et al. 2011; Dang et al. 2012; Calvier et al. 2013; Traber et al.
2013; Yu et al. 2013), but also in two well-characterized rodent mod-
els of lung fibrosis, adeno-viral TGF-β1- and bleomycin-induced
(MacKinnon et al. 2012), galectin-3 appears to be a mediator of in-
jury. This effect, though often related to its proinflammatory action,
is likely due to its ability to directly mediate TGF-β1-induced transdif-
ferentiation into collagen-producing cells. Maeda et al. (2003) showed
that galectin-3 induces hepatic stellate cells’ transdifferentiation into
myofibroblasts via the MAPK/extracellular signal-regulated kinase
(ERK)–ERK 1/2 signaling pathway and, at variance with galectin-1,
in a protein kinase C- and A-dependent manner. MacKinnon et al.
(2012) showed that galectin-3 ablation reduces alveolar cell EMT in
response to TGF-β1. Conversely, under the conditions of increased
AGE/ALE levels such as diabetes and related metabolic disorders,
the protective properties of this lectin toward AGE/ALE-induced tissue
inflammation and injury prevail, a possible explanation for the accel-
erated organ damage observed in mice lacking galectin-3 (Pugliese
et al. 2001; Iacobini et al. 2004; Iacobini et al. 2005; Iacobini et al.
2009a; Iacobini et al. 2009b). However, this was not always the
case, with early retinal lesions (Canning et al. 2007) and liver injury
(Iacobini et al. 2011) being reduced instead of enhanced by galectin-3
ablation. It seems plausible that AGE/ALE-independent actions of
galectin-3, such as chemoattraction and activation of inflammatory
cells, could have played a role in the early retinal changes observed
by Canning et al. (2007) In fact, after 3 weeks of diabetes, AGE levels
were only modestly elevated in diabetic versus nondiabetic mice, were
not modified by the AGE inhibitor pyridoxamine, and did not differ
between gelectin-3 knockout and wild-type animals. Conversely, pre-
vention of HFD-induced NASH might reflect the unique scavenging
function of galectin-3 in the liver and the central role of this organ
in AGE/ALE catabolism. Accordingly, galectin-3 ablation would re-
sult in reduced liver uptake and content of these by-products and in-
creased circulating AGE/ALE levels. Conversely, AGEs/ALEs
accumulate in other tissues/organs, such as the kidney and vessels,
where their production is increased and removal is impaired by the ab-
sence of galectin-3 (Figure 4).
A major issue of debate in studies on the models of metabolic dis-
orders is that lesions were accelerated when galectin-3 ablation was as-
sociated with increased tissue AGE/ALE levels and consequent RAGE
over-expression (i.e., in the kidney and aorta) and attenuated when
Table II. Effects of galectin-3 ablation or inhibition on liver disease
Authors,
year
Experimental model Disease outcome Major findings Mechanisms
Nomoto
et al. 2006
Gal-3 ablation Spontaneous NAFLD
in 6- month male
mice:
Mild-to-severe steatosis, acute and
chronic lobular inflammation,
increased triglyceride, lipid peroxide
and serum alanine aminotransferase
levels.
Increased AGE/RAGE-induced
inflammation and injury
Increased PPARγ
Nakanishi
et al. 2008
Gal-3 ablation Spontaneous
hepatocellular
carcinoma in mice
older than 15
months
Dysplastic liver nodules and
hepatocellular carcinoma by
contrast-enhanced computed
tomography and histology
Liver carcinogenesis based on
a natural history of NAFLD
Iacobini et al.
2011
Dyslipidemia: Paigen diet (Gal-3
ablation)
Protection from
diet-induced NASH
Reduced steatosis, hepatocyte
degeneration, lobular and portal
inflammation, fibrosis, upregulation
of hepatic fatty acid synthesis, AGE/
ALE levels and RAGE expression
Reduced AGE/ALE liver uptake
from the bloodstream by
sinusoidal liver epithelial cells
Prevention of AGE/ALE
tissue accumulation, RAGE
upregulation and related
inflammation and injury
Henderson
et al. 2006
CCL4-induced cirrhosis (Gal-3
ablation) and hepatic stellate
cell cultures (Gal-3 silencing)
Protection from
hepatic fibrosis
Attenuated ECM production
Reduced myofibroblast activation
Blunted TGF-β-mediated
myofibroblast activation
and matrix production
Traber et al.
2013
Thioacetamide-induced fibrosis
(Gal-3 inhibition)
Protection from
hepatic fibrosis,
reversal of cirrhosis
Reduced collagen content, portal and
septal inflammation, ballooning and
portal pressure
Not conclusively identified:
Reduced stellate cell
activation and/or changes in
the cytokine/ inflammatory
milieu
Gal-3, galectin-3; NAFLD, nonalcoholic fatty liver disease; AGE, advanced glycation end-product; RAGE, receptor for AGEs; PPAR-γ, peroxisome
proliferator-activated receptor γ; NASH, nonalcoholic steatohepatitis; ALEs, advanced lipoxidation end-products; CCL4, carbon tetrachloride; ECM, extracellular
matrix; TGF-β, transforming growth factor β.
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absence of this lectin resulted in reduced ALE/ALE accumulation and
lack of stimulation of RAGE expression (i.e., in the liver) (Figure 3).
This suggested the view that galectin-3 could only play a supportive
role through a dual, tissue-specific modulation of RAGE expression,
depending on the anabolic or catabolic role of the tissue in the metab-
olism of AGEs/ALEs. This view is supported by the observations that
(i) diabetic glomerulopathy was accelerated in transgenic mice over-
expressing RAGE (Yamamoto et al. 2001); (ii) diabetes-induced
atherogenesis was attenuated in ApoE null mice by RAGE blockade
with soluble RAGE (Park et al. 1998) and (iii) liver fibrosis induced
by administration of carbon tetrachloride to normal rats was amelio-
rated by RAGE silencing (Xia et al. 2008).
However, other findings suggest that galectin-3 is not simply a
“stooge” of RAGE, but participates in the complications of metabolic
disorders by exerting direct RAGE-independent effects. These include
the AGE/ALE scavenging function in the liver, the lack of which
reduces the uptake of these by-products (Iacobini et al, 2011), as dis-
cussed in the Liver disease section.
Moreover, the distinct inflammatory features of galectin-3 knock-
out animals at the aortic (Iacobini et al. 2009a) and possibly renal
(Pugliese et al. 2001; Iacobini et al. 2004; Iacobini et al. 2005; Iacobini
2009b) level may be explained also by the lack of the direct antiinflam-
matory actions of this lectin, likely as the consequence of a dysregu-
lated T-cell function due to disturbed galectin-glycoprotein lattice at
the cell surface and/or lack of intracellular actions of galectin-3. Like-
wise, the lack of the profibrotic effect of galectin-3 may participate in
the attenuation of NASH (Iacobini et al. 2011) and, together with the
impaired clearance of apoptotic cells favored by the absence of this lec-
tin, to the enlargement of the necrotic core and thinning of the fibrous
cap in plaques (Iacobini et al. 2009a). Finally, the stimulation of
VSMC osteogenic differentiation leading to the formation of macro-
calcification represents another mechanism by which galectin-3
might limit inflammation within the vessel wall, thus favoring stabil-
ization and reducing progression of atherosclerotic plaques (Menini
et al. 2013). This effect appears to be mediated via the Wnt/β-catenin
signaling (Menini et al. 2013). In this view, galectin-3 appears to func-
tion as a regulatory molecule acting at various stages along the con-
tinuum from the initiation phase of inflammation, through the
walling off of tissue injury via promotion of fibrogenesis and/or calci-
fication, to the final repair of damage. This is consistent with the report
that galectin-3 plays a dynamic role in the regulation of skin wound
healing (Gál et al. 2011).
Galectin-3 in chronic low-grade inflammation
associated with type 2 diabetes and related
metabolic disorders
Type 2 diabetes and related metabolic disorders are reaching epidemic
proportions worldwide (Daar et al. 2007). It has now become clear
that low-grade chronic inflammation is a key player in the pathogen-
esis of these disorders (Dandona et al. 2004). Therefore, characteriza-
tion of the immune pathways that initiate, sustain and modulate
inflammation in tissues involved in the regulation of glucose homeo-
stasis, such as adipose tissue and pancreatic islets, could be of thera-
peutic importance. Cells of the adaptive and innate immunity with
regulatory and antiinflammatory properties, such as regulatory T
cells, T cells with Th-2 phenotype and alternatively activated M2
macrophages protect adipose tissue from inception of chronic, low-
grade inflammation induced by overnutrition (Hong et al. 2009;
Fig. 4. Postulated effect of galectin-3 deletion on renal, vascular and liver disease inmetabolic disorders. In kidney and vessels, where AGEs/ALEs are produced to an
increased extent, lack galectin-3 impairs their removal, leading to increased RAGE-mediated injury and accelerated renal disease and atherosclerosis. In contrast, in
the liver, lack of galectin-3 results in reduced uptake and tissue accumulation of these by-products, with consequent increased circulating and reduced liver tissue
AGE/ALE levels and attenuatedNASH. The lack of immune-modulatory action and pro-fibrotic effect of galectin-3mayalso play a role. ROS, reactive oxygen species;
AGE, advanced glycation end-product; ALE, advanced lipoxidation end-products; RAGE, receptor for AGEs; NASH, nonalcoholic steatohepatitis; LSECs, liver
sinusoidal endothelial cells; KCs, Kupffer cells.
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Nishimura et al. 2009). Recent evidence suggested that galectin-3
might be involved in the regulation of glucose homeostasis by acting
at the level of adipose tissue and pancreatic islets, thus participating in
the pathogenesis of obesity, type 2 diabetes and the metabolic syn-
drome. Moreover, disturbed metabolism might influence N-glycan
synthesis and branching, resulting in altered galectin-glycoprotein lat-
tice, thus affecting galectin-3 function (Dennis, Lau, et al. 2009; Den-
nis, Nabi, et al. 2009).
Adipose tissue and systemic inflammation
Previous studies have indicated that circulating levels of galectin-3 and
adipose tissue production of this lectin are elevated in both obese hu-
mans and experimental animal models of obesity, with higher expres-
sion in visceral adipose tissue (VAT) than in subcutaneous adipose
tissue (Weigert et al. 2010).
More recently, two independent research laboratories have inves-
tigated the role of galectin-3 in the modulation of metabolic disorders
by the use of galectin-3 knockout mice fed an obesogenic HFD con-
taining 60% calories from saturated fat. Their results have been simi-
lar and complementary, pointing to a protective role of galectin-3
toward obesity and type 2 diabetes, via modulation of the responsive-
ness of innate and adaptive immunity to overnutrition (Pang et al.
2013; Pejnovic et al. 2013). In particular, Pejnovic et al. (2013)
have shown that galectin-3 knockout mice fed an HFD have in-
creased (i) body weight and amount of VAT; (ii) systemic inflamma-
tion and (iii) adipose tissue expression and/or activation of NFκB and
the nucleotide-binding and oligomerization domain, leucine-rich re-
peat and pyrin domain containing three (NLRP3) inflammasomes.
Likewise, Pang et al. (2013) showed that HFD-induced increases in
body weight, fat mass and circulating levels and VAT release of leptin,
and decreases in VAT mRNA levels of adiponectin and peroxisome
proliferator-activated receptor (PPAR) γ, were significantly higher
(except for PPARγ decrease) in galectin-3 knockout than in the cor-
responding wild-type mice. This was associated with evidence of
more marked systemic inflammation in HFD-fed galectin-3 knockout
versus wild-type mice. In both studies, increased adiposity and in-
flammation at the VAT and systemic level were associated with al-
tered glucose homeostasis, as evidenced by increased fasting
glucose and glycated hemoglobin levels (Pang et al. 2013; Pejnovic
et al. 2013).
While Pejnovic et al. (2013) attributed their results to the lack of the
antiinflammatory action of galectin-3, with consequent enhancement of
chronic, low-grade inflammation induced by excess dietary fat (Rhodes
et al. 2013), the results of Pang et al. (2013) are difficult to reconcile
with the proinflammatory effect of the HFD. In fact, at variance with
Pejnovic et al. (2013), they found that increased adiposity, VAT and sys-
temic inflammation and altered glucose homeostasis occurred also in
galectin-3 knockout mice fed a standard diet (Pang et al. 2013), thus
suggesting a reduction of age-induced inflammation and metabolic dys-
function and also a direct effect of galectin-3 on adipogenesis. Indeed, in
human adipose tissue, galectin-3 is expressed not only by macrophages
but also by adipocytes (Rhodes et al. 2013), where its expression is
modulated during cell differentiation, being high in the preadipocyte
fraction and almost nil in differentiated adipocytes (Kiwaki et al.
2007). Moreover, it was found that recombinant human galectin-3 sti-
mulates preadipocyte proliferation as well as DNA synthesis through
lectin–carbohydrate interaction (Kiwaki et al. 2007). The implication
of galectin-3 in the modulation of preadipocyte differentiation is also
consistent with a previous report showing that this lectin stimulates
the growth of fibroblasts (Arar et al. 1998). This would explain the
significantly higher fat mass and levels of circulating and VAT leptin
in galectin-3 knockout mice irrespective of diet (Pang et al. 2013).
Pancreatic islets
Galectin-3 has been shown to be the most upregulated protein in rat
pancreatic islets exposed to interleukin-1β (IL-1β); moreover, its over-
expression protected β-cells from the cytotoxic effect of IL-1β (Karlsen
et al. 2006). In contrast, targeted disruption of the galectin-3 gene re-
sulted in reduced susceptibility to multiple low-dose streptozotocin-
induced diabetes in mice (Mensah-Brown et al. 2009).
In addition to VAT, Pejnovic et al. (2013) found increased inflamma-
tion also in pancreatic islets from galectin-3 knockout mice fed anHFD,
as demonstrated byamarked infiltration of cells of themacrophage/den-
dritic lineage, with various degrees of insulitis. This was associated with
increased activation of NFκB and expression/activation of the NLRP3
inflammasome, as evidenced by significantly higher NLRP3- and
IL-1β-positive area and increased expression of apoptosis-associated
speck-like protein containing a caspase recruitment domain (ASC),
procaspase-1 and mature caspase-1 in HFD-fed galectin-3 knockout
mice, whereas HFD-fed wild-type mice showed only increased ASC ex-
pression versus the corresponding animals on standard chow. These
authors also showed that galectin-3 knockout mice fed an HFD had in-
creased accumulation of AGEs in islets (Pejnovic et al. 2013), a finding
in keeping with the AGE receptor function of galectin-3, which favors
AGE degradation (Iacobini et al. 2003). Increased AGE levels could be
involved in NLRP3 inflammasome activation in islet cells or infiltrating
macrophages (Pejnovic et al. 2013). Moreover, in addition to the per-
missive effect of galectin-3 deletion on RAGE expression (Iacobini
et al. 2003), AGEs could also be involved in RAGE upregulation
and activation, thus participating in the increased IL-1β expression, a
common proinflammatory mediator involved in β-cell destruction and
impaired insulin secretion in both type 1 and type 2 diabetes (Dinarello
et al. 2010). These data indicate an important role of galectin-3 in pro-
tecting islets from inflammation and injury induced by a variety of stim-
uli associated with overfeeding, including AGEs.
At variance with Pejnovic et al. 2013), Pang et al. (2013) showed
that, in galectin-3 knockout mice fed an HFD, impaired glucose metab-
olism was not associated with a more marked insulin resistance as com-
pared with the corresponding wild-type animals, as evidenced by the
similar increases in insulin levels and homeostatic model assessment
index—insulin resistance index anddecrease in the response to an insulin
tolerance test. Moreover, they found that increased fasting glucose and
altered responsiveness to a glucose load preceded the development of
excess adiposity and VAT and systemic inflammation, based on the evi-
dence that young (12-week- old) galectin-3 knockout mice fed a stand-
ard diet exhibited altered glucose homeostasis in the absence of obesity
and associated abnormalities. These data point to a direct modulation of
β-cell function by galectin-3 independent of obesity-related inflamma-
tion. This view is consistent with the finding that the circulating levels
of galectin-3 observed in patients with type 2 diabetes were negatively
correlated with glycated hemoglobin (Weigert et al. 2010).
Galectin-3: A new player in metabolic disorders?
Collectively, these data suggest that galectin-3 has a protective role
in type 2 diabetes and related metabolic disorders by attenuating
HFD- and age-induced inflammation at both systemic and local (meta-
bolic tissues) level. This might result in reduction of insulin resistance
and β-cell dysfunction, that is, the major contributors to the pathogen-
esis of type 2 diabetes (Figure 5). Indeed, galectin-3 seems to be in-
volved in the modulation of the activation of NF-κB and the NLRP3
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inflammasome, two pathways shown to exert important proinflam-
matory actions at both the adipose tissue and pancreatic level in the
setting of obesity and type 2 diabetes (Wen et al. 2012).
However, current evidence indicates that galectin-3 exerts other ef-
fects on glucose homeostasis, which are independent of its immuno-
modulatory function. These effects might include the modulation of
adipogenesis and also the regulation of β-cell function through as
yet unidentified mechanisms. Further research is needed to elucidate
the overall contribution of galectin-3 to metabolic regulation and
the molecular mechanisms involved.
Conclusions
Galectin-3 is a versatile molecule serving as a broad-spectrum biological
response modifier and exerting numerous and sometimes opposite func-
tions. As a consequence, it participates in a wide spectrum of acute and
chronic diseases, including metabolic disorders and their complications,
with varying effects according to the type of injurious stimulus, the con-
text of organ damage and the localization of galectin-3. In particular, at
the cell surface, it interacts with N-glycans to form lattice structures,
which regulate several biological functions including promotion of
CLIC biogenesis, thus modulating cell growth, (trans)differentiation
and motility as well as inflammation and fibrogenesis. Moreover, it fa-
vors the internalization and removal of AGEs/ALEs, though themolecu-
lar mechanism underlying this function is still unknown and might also
involve the galectin-glycoprotein lattice. Also intracellular gelactin-3 is
involved in mediating the cell cycle-regulating and immunomodulatory
actions at the cytoplasmic and nuclear level.
In the pathogenesis of complications of diabetes and related meta-
bolic disorders, the AGE/ALE-receptor and scavenging function of
galectin-3 seems to be the main mechanism involved, with opposite ef-
fects depending on the anabolic or catabolic role of the tissue in the me-
tabolism of these harmful by-products. In fact, the content of ALEs/
AGEs is increased in those tissues that are the target of diabetic
complications, such as the kidney and vessels, where AGEs/ALEs are
produced to an increased extent and the absence of galectin-3 impairs
their removal, thus accelerating lesions. In contrast, in the liver, AGE
and ALE tissue content and injury are decreased, since the lack of
the scavenging function of galectin-3 results in reduced liver uptake
and accumulation of these by-products. Some of these effects can be
explained by changes in the expression of RAGE associated with
galectin-3 deletion and consequent changes in AGE/ALE tissue levels.
In addition, galectin-3 exerts AGE/ALE- and RAGE-independent ef-
fects, favoring resolution of inflammation and modulating fibrogenesis
and ectopic osteogenesis, particularly in the setting of atherosclerosis.
These effects are mediated by intracellular and extracellular galectin-3,
the latter via interaction with N-glycans at the cell surface to form lat-
tice structures, though specific studies are needed to confirm a major
role for this mechanism in the context of diabetic complications.
Recently, galectin-3 has been shown to have also a protective role in
the development of type 2 diabetes and related metabolic disorders,
by favoring the maintenance of glucose homeostasis and preventing
the deleterious activation of adaptive and innate immune response as
a result of obesogenic and diabetogenic stimuli. In addition to its
immuno-modulatory properties, other as yet unknown actions of
galectin-3 might be involved in the regulation of adipose tissue and
β-cell function.
Altogether, these data indicate that galectin-3 is an emerging all-
out player in metabolic disorders and their complications, which is
worthy of further investigation as a target of therapeutic relevance.
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